Skip to content

Pimavanserin

    Brands

    DEA Class;  Rx

    Common Brand Names; Nuplazid

    • Antipsychotics, 2nd Generation; 
    Atypical antipsychotic with serotonin modulator activity
    Used for hallucinations and delusions associated with Parkinson’s disease psychosis; not approved for patients with dementia-related behavioral problems unrelated to Parkinson’s disease psychosis
    May cause QT prolongation; avoid use with other drugs that prolong the QT interval and avoid in patients with risk factors for QT prolongation

    Indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

    Documented hypersensitivity reaction to drug or components; rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea)

    Nausea (7%)

    Peripheral edema (7%)

    Confusional state (6%)

    Hallucinations (5%)

    Constipation (4%)

    Gait disturbance (2%)

    Rash

    Urticaria

    Reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea)

    Somnolence, falls

    Agitation

    Aggression

    Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis (see Black Box Warnings)

    Pimavanserin is a substrate of CYP3A4; strong CYP3A4 inhibitor or inducers affect systemic exposure (see Dosage Modifications and Interactions)

    There are no data for use in pregnant women that would allow assessment of the drug-associated risk of major congenital malformations or miscarriage

    Unknown if distributed in human breast milk

    Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

    Adults

    34 mg/day PO.

    Geriatric

    34 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Not indicated.

    Pimavanserin

    capsule

    • 34mg

    tablet

    • 10mg